KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Thermo Fisher Scientific (TMO) over the last 17 years, with Q3 2025 value amounting to $227.0 million.

  • Thermo Fisher Scientific's Depreciation and Depletion fell 2199.31% to $227.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 576.24%. This contributed to the annual value of $1.2 billion for FY2024, which is 823.97% up from last year.
  • Per Thermo Fisher Scientific's latest filing, its Depreciation and Depletion stood at $227.0 million for Q3 2025, which was down 2199.31% from $256.0 million recorded in Q2 2025.
  • Thermo Fisher Scientific's 5-year Depreciation and Depletion high stood at $304.0 million for Q4 2024, and its period low was $198.0 million during Q2 2021.
  • Its 5-year average for Depreciation and Depletion is $252.6 million, with a median of $256.0 million in 2022.
  • In the last 5 years, Thermo Fisher Scientific's Depreciation and Depletion soared by 3439.49% in 2021 and then plummeted by 2199.31% in 2025.
  • Quarter analysis of 5 years shows Thermo Fisher Scientific's Depreciation and Depletion stood at $217.0 million in 2021, then rose by 17.97% to $256.0 million in 2022, then rose by 7.81% to $276.0 million in 2023, then grew by 10.14% to $304.0 million in 2024, then dropped by 25.33% to $227.0 million in 2025.
  • Its Depreciation and Depletion stands at $227.0 million for Q3 2025, versus $256.0 million for Q2 2025 and $276.0 million for Q1 2025.